Table 1.
Other respondents n = 140 (69.3%) | Respondents identified with current/former injection drug users n = 62 (30.7%) | Total N = 202 | p value | |
---|---|---|---|---|
n (%) | n (%) | N (%) | ||
Age median [IQR] (n = 189) | 39 [31–51] | 48 [36–57] | 42 [33–52] | 0.003 |
Gender (n = 200) | 0.393 | |||
Male | 76 (54.7) | 37 (60.7) | 113 (56.5) | |
Female | 60 (43.2) | 21 (34.4) | 81 (40.5) | |
Transgender | 1 (0.7) | 1 (1.6) | 2 (1.0) | |
Gender non-binary | 2 (1.4) | 2 (3.3) | 4 (2.0) | |
Living area (n = 199) | 0.022 | |||
Urban area/large city/Near a large city | 93 (67.4) | 44 (72.1) | 137 (68.8) | |
Semi-urban area/small or medium city | 33 (23.9) | 6 (9.8) | 39 (19.6) | |
Rural area/Village | 12 (8.7) | 11 (18.0) | 23 (11.6) | |
Highest level of education completed (n = 198) | 0.379 | |||
Never went to school/primary/secondary (middle school/high school) | 15 (10.8) | 9 (15.3) | 24 (12.1) | |
Tertiary (college, university, or vocational training) | 124 (89.2) | 50 (84.7) | 174 (87.9) | |
Previously tested for HCV (n = 201) | 0.001 | |||
Yes | 90 (64.3) | 55 (90.2) | 145 (72.1) | |
No/I do not know | 50 (35.7) | 6 (9.8) | 56 (27.9) | |
Previously tested positive for HCV (n = 139)a | < 0.001 | |||
Yes | 19 (22.6) | 38 (69.1) | 57 (41.0) | |
No | 65 (77.4) | 17 (30.9) | 82 (59.0) | |
Previously tested positive with RNA PCR for HCV (n = 57)b | NA | |||
Yes | 18 (94.7) | 36 (94.7) | 54 (94.7) | |
No/I do not know | 1 (5.3) | 2 (5.3) | 3 (5.3) | |
Previous treatment for HCV (n = 53)c | 0.153 | |||
Yes | 18 (100.0) | 30 (85.7) | 48 (90.6) | |
No | 0 (0.0) | 5 (14.3) | 5 (9.4) |
Missing values were excluded of this comparison/P-values in bold are significant
aAmong those previously tested for HCV
bAmong those previously tested positive for HCV
cAmong those previously tested positive with RNA HCV for HCV